Section 232 Pharmaceutical Tariff Takes Effect: A 100% Duty on Patented Drugs and APIs

A 100 percent tariff on certain patented pharmaceutical products and their active pharmaceutical ingredients began taking effect July 31, 2026, the culmination of a Section 232 national security investigation the US Department of Commerce opened on April 1, 2025. The White House issued the underlying proclamation on April 2, 2026, and built in a staggered rollout: July 31, 2026 (120 days after the proclamation) applies only to the 17 companies named in the proclamation's Annex III, major innovator drugmakers with existing US onshoring or pricing agreements, including AbbVie, Pfizer, and Novartis, while every other pharmaceutical company and product within the tariff's scope faces a later effective date of September 29, 2026 (180 days after the proclamation). For any Thailand-based pharmaceutical ingredient exporter, contract manufacturer, or finished-dose producer shipping toward the US market and not supplying one of those 17 Annex III companies, the real compliance deadline is September 29, 2026, not July 31, and this is one of the most significant single tariff actions of the 2025-2026 trade environment, layering directly on top of the separate reciprocal tariff arrangement Thailand negotiated with the US in October 2025.

What the Section 232 pharmaceutical tariff covers

Section 232 of the Trade Expansion Act of 1962 lets the President impose tariffs on imports that the Commerce Department determines threaten to impair US national security, a legal basis that has previously been used for steel, aluminum, and now, following the same procedural path, pharmaceuticals and semiconductors (covered separately in this update series). The Commerce Department's investigation, opened in April 2025, examined whether US reliance on foreign-sourced pharmaceutical products and active pharmaceutical ingredients (APIs), the chemical compounds that provide a drug's therapeutic effect before formulation into a finished dose, created a national security vulnerability. Roughly a year later, the White House proclaimed a 100 percent tariff on imports of certain patented pharmaceutical products and associated APIs, phased in July 31, 2026 for the 17 Annex III companies with onshoring agreements and September 29, 2026 for everyone else in scope.

The tariff's scope is specifically targeted at patented pharmaceutical products, meaning branded, patent-protected drugs and their associated API inputs, rather than a blanket duty on all pharmaceutical trade. Generic pharmaceutical products and APIs used exclusively in generic manufacturing fall outside this particular proclamation's core target, based on the law firm reporting describing the action. That distinction matters enormously for a Thailand-based contract manufacturer or API supplier, because a company's actual tariff exposure now depends on the patent status of the specific molecule and finished product it is shipping, not simply on the product category of "pharmaceutical" as a whole.

Why a 100 percent tariff changes the underlying economics, not just the margin

A 100 percent tariff is not a marginal cost adjustment that a company can absorb through pricing discipline or supply chain efficiency. It doubles the landed cost of a covered product entering the US market, which for many patented pharmaceutical products and APIs is enough to make continued export at existing pricing commercially unviable, regardless of how competitively the product was priced before the tariff took effect. For a Thailand-based API manufacturer or contract development and manufacturing organization (CDMO) currently supplying a patented drug's API or intermediate product toward the US market, the tariff forces a genuine strategic decision rather than a pricing adjustment: absorb the cost and renegotiate contract terms with the US-based innovator company, restructure the supply relationship so that only the non-covered generic or off-patent portion of the business continues moving toward the US, or shift that portion of production capacity toward non-US markets where the tariff does not apply.

How this interacts with the US-Thailand reciprocal trade framework

This tariff sits on top of, not instead of, the separate 19 percent reciprocal tariff rate the US and Thailand agreed to under their October 2025 framework agreement. The reciprocal tariff framework negotiated a general baseline rate for Thai-origin goods entering the US market and included a zero-tariff carve-out list under Executive Order 14346's Annex III, alongside a Thai commitment to accept US FDA certifications for medical devices and pharmaceuticals moving in the other direction. Nothing in the public reporting on the reciprocal framework suggests it displaces or exempts products from a separately imposed Section 232 national security tariff; Section 232 tariffs and reciprocal or country-specific tariff rates have historically been treated by US Customs and Border Protection as independent, potentially stacking duty regimes rather than alternatives a company can choose between. A Thailand-based pharmaceutical exporter should not assume that qualifying for the reciprocal framework's more favorable general treatment provides any shelter from the separate 100 percent Section 232 tariff if its specific product falls within that proclamation's patented-pharmaceutical and API scope.

What Thailand-based pharmaceutical exporters should do now

The first and most consequential step for any Thailand-based API manufacturer, CDMO, or finished-dose exporter is confirming, product by product, whether what is being shipped toward the US actually falls within this proclamation's scope. That requires establishing the patent status of both the API and the finished pharmaceutical product it will be formulated into or is already part of, since the tariff is targeted at patented products specifically rather than pharmaceuticals broadly. A company manufacturing API exclusively for generic formulations, or supplying a molecule whose patent protection has already lapsed, may sit entirely outside this tariff's scope even while operating in the same general product category as a company that is squarely inside it.

For companies confirmed to be within scope, the practical response involves working directly with US-based customers and innovator partners on how the tariff cost is allocated contractually, since in most supply arrangements the importer of record, not the Thai exporter, is the party who pays the tariff at the US border, but the economic burden inevitably gets renegotiated back through pricing and contract terms across the supply chain. Companies should also revisit whether any portion of their current US-bound product mix can be reclassified, restructured, or shifted toward non-patented, non-US markets to reduce total exposure, and should treat this tariff as a live variable in ongoing customer contract negotiations rather than a one-time cost absorbed at the July 2026 effective date and then forgotten.

DeeMED's Global Trade compliance services help Thailand-based pharmaceutical exporters and CDMOs confirm Section 232 scope status and coordinate that analysis with US FDA and reciprocal-tariff-framework considerations, so a company understands its actual combined duty exposure rather than treating each tariff regime in isolation.